Amsterdam/Wageningen – Caelus Health, which develops food supplements and pharmaceutical products for the prevention and early treatment of cardio-metabolic diseases, is closely working with Wageningen University & Research (WUR). Extensive research has resulted in the discovery of pathway by which dietary inositol is efficiently converted in propionate and acetate: a new inositol pathway, which has now been published in Nature Communications.
The identification of this new pathway forms the basis of new IP and additional options to assess the mechanisms of action (MoA) by which innovative microbiota may contribute to health and increase the understanding how to enhance cardiometabolic health, in particular in individuals at risk of Type 2 Diabetes.
In the past decade ground-breaking research at Wageningen University & Research (a.o. the Laboratory of Microbiology) has resulted in numerous publications and patents regarding gastrointestinal and metabolic disorders demonstrating the relevance of gut microbiota in the pathophysiology and management of related diseases. In particular various new anaerobic microbes have been identified and characterised. Prof Willem M. de Vos, who served as Distinguished Professor at Wageningen University & Research commented on the most recent results: “By using a combination of genome, proteome and metabolome studies enriched with 13C NMR analysis, we unravelled a novel pathway involved in the conversion of inositol into acetate and propionate, important signalling metabolites in the human gut that were shown to improve metabolic health in a mouse model. Of note, the new genes for this pathway were enriched in the gut microbiota of healthy subjects as compared to patients with type 2 diabetes.”
Wageningen University & Research is a strategic partner of Caelus Health in the identification, characterisation and further development of innovative microbiota-based products. Understanding the biological pathways and MoA is an important element in development and registration of microbiota products. Luc Sterkman, MD, states as CEO of Caelus: “The latest findings in Wageningen contribute to broadening and deepening our pipeline of microbiota-based products and further combination products, such as combinations with inositol.”
About Caelus Health
Caelus Health is an Amsterdam-based biotech company. Caelus is dedicated to the commercialisation of functional food and pharmaceutical products for the prevention and early treatment of cardio-metabolic diseases. Based on the strong correlation between the intestinal microbiome and health, the company is developing an entirely new class of microbiota-based therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes Mellitus (T2DM) in people with metabolic syndrome (MetS). In addition, the company has built an extensive range of patents based on the gut microbiome and fecal Microbiota Transplant (FMT) -studies In Type 1 Diabetes, cancer cachexia and liver disorders.
Focusing on the mission ‘To explore the potential of nature to improve the quality of life’, Wageningen University & Research (WUR) combines fundamental and applied knowledge in order to contribute to resolving important questions in the domain of healthy food and living environment. Over 6,500 employees (over 5,500 fte) and more than 12,000 students are inspired by nature, society, and technology and tackle the issues with an open and curious perspective. This inspiration has enabled WUR to be amazed, develop knowledge, and apply this knowledge internationally for over a century. We collaborate with governments, companies, non-governmental organisations and other research institutes. www.wur.eu
For more information, please contact
LGW Sterkman, CEO Caelus Health: email@example.com tel: +31-6-22979249